2024/09/18 08:02:19 | |
---|---|
Price | |
0.1456 EUR | |
Difference | -46.76% (-0.13) |
ISIN | NL0014040206 |
Symbol | 39K |
Exchange | Stuttgart |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 8 EUR |
Benchmark | GERMANY DAX |
Bid (Bid size) | 0.1456 EUR (5,000) |
Ask (Ask size) | 0.289 EUR (5,000) |
Open | 0.1456 EUR |
High | 0.1456 EUR |
Low | 0.1456 EUR |
Close (prev. day) | 0.2735 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/09/11 | Global Equity Ratings | ||
2024/09/05 | Global Equity Ratings | ||
2024/08/12 | Global Equity Ratings | ||
2024/07/24 | Global Equity Ratings | ||
2024/07/12 | Global Equity Ratings |
2024/09/18 08:02:19 | |
---|---|
Price | |
0.1456 EUR | |
Difference | -46.76% (-0.13) |
ISIN | NL0014040206 |
Symbol | 39K |
Exchange | Stuttgart |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 8 EUR |
Benchmark | GERMANY DAX |
Bid (Bid size) | 0.1456 EUR (5,000) |
Ask (Ask size) | 0.289 EUR (5,000) |
Open | 0.1456 EUR |
High | 0.1456 EUR |
Low | 0.1456 EUR |
Close (prev. day) | 0.2735 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
6m | 1Y | 3Y | |
Perf (%) | -61.26% | -69.20% | -96.83% |
Perf (abs.) | -0.43 | -0.61 | -8.35 |
Beta | - | - | - |
Volatility | 193.82 | 152.91 | 139.51 |
Ø price 5 days | Ø volume 5 days (pcs.) | 0.2031 EUR (18,057) |
Ø price 30 days | Ø volume 30 days (pcs.) | 0.1805 EUR (5,944) |
Ø price 100 days | Ø volume 100 days (pcs.) | 0.2938 EUR (1,801) |
Ø price 250 days | Ø volume 250 days (pcs.) | 0.6194 EUR (789) |
YTD High | date | 1.1350 EUR (2024/01/10) |
YTD Low | date | 0.0800 EUR (2024/09/02) |
52 Weeks High | date | 1.2550 EUR (2023/11/01) |
52 Weeks Low | date | 0.0800 EUR (2024/09/02) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Stuttgart | 2024/09/18 | 08:02 | 0.1456 EUR | 0.00 | 1 |
Nasdaq | 2024/08/07 | 22:00 | 0.325 USD | 4.17 | 15,228 |
Munich | 2024/09/18 | 08:03 | 0.2495 EUR | 0.00 | 1 |
Hamburg | 2024/09/18 | 08:16 | 0.10 EUR | 0.00 | 1 |
Frankfurt | 2024/08/20 | 16:47 | 0.20 EUR | 0.00 | 2 |
FINRA other OTC Issues | 2024/09/18 | 15:30 | 0.20 USD | 0.00 | 3 |
Duesseldorf | 2024/08/09 | 09:30 | 0.2995 EUR | 0.00 | 2 |
Berlin | 2024/09/18 | 15:39 | 0.2165 EUR | 0.00 | 11 |
CENTOGENE NV |
- - |
Am Strande 7 - 18055 Rostock |
Telefon: +49-381-80113400 |
Fax: +381-80113401 |
E-mail: - |
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. It operates through the following segments: Pharmaceutical, Diagnostics, and Corporate. The Pharmaceutical segment provides solutions to pharmaceutical partners, including target discovery, early patient recruitment and identification, epidemiological insights, and biomarker discovery. The Diagnostics segment offers genetic sequencing and diagnostics services to clients, who are typically physicians, laboratories, or hospitals, either directly or through distributors. The Other segment covers COVID-19 testing services to clients. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark. |
Kim Stratton | Chairman of Managing Board |
Ian Rentsch | Member of Executive Committee |
Miguel Coego Rios | Member of Executive Committee |
Peter Bauer | Member of Executive Committee |
Peer Schatz | Chairman of Supervisory Board |
Eric Souêtre | Member of Supervisory Board |
Hubert Birner | Member of Supervisory Board |
Jonathan Sheldon | Member of Supervisory Board |
Guido Prehn | Member of Supervisory Board |
Mary Sheahan | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer